Browse Drugs Alphabetically:
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Request Attorney Assistance

Please complete all the fields below to send the bad drug report. Each field is required to be completed in order to send. The submission of this form does not form an attorney client relationship. An attorney client relationship will only be formed after the execution and return of a retainer agreement.

Januvia and Janumet

Author: celeste garza
Posted on Sep 26, 2013 in bad-drug-blog

Januvia and Jamumet are drugs that are used to treat type 2 diabetes . Both are dangerous drugs that have serious side effects including pancreatitis and pancreatic cancer. Merck & Co., the company that makes Januvia and Janumet, have been the losing defendant in many negligence lawsuits. In litigation proceedings, plaintiffs accuse Merck of negligence and concealing the risks of these significant side effects.

Januvia and Janumet

Januvia (sitagliptin) is used to treat type two diabetes. It is made to be used along with exercising and eating a healthy diet. Our bodies produce incretin – a hormone released from intestinal cells – after we eat and our blood sugar rises. Incretin stimulates pancreatic cells called beta cells to release insulin. Insulin is the ingredient that is needed to metabolize sugar and signals to the liver to stop making excess sugar. Then, in people without diabetes, DPP-4 is what keeps a balance between blood sugar and insulin levels. There is already too much sugar in the blood for diabetics.

Januvia blocks DPP-4, allowing incretin to stay in the blood longer and to continue stimulating the pancreas into make more insulin to remove excess sugar. People who have excess ketones in the blood or urine – a condition known as diabetic ketoacidosis – should not take Januvia or Janumet.

Jamumet is combines sitagliptin and melformin. Melformin works by decreasing glucose (sugar) production in the liver and decreasing absorption of glucose by the intestines. Jamumet can be used along with diet and exercise to lower blood sugar in adults with type 2 diabetes.

Januvia and Janumet and FDA Lawsuits

Since the FDA approval in October 2006, Januvia has raised many flags and is to blame in multiple lawsuits. Federal Drug Administration (FDA), European Medicines Agency (EMA) and American Diabetes Association (ADA) have been in many debates regarding the safety of sitagliptin, the active ingredient in Januvia and Jamumet.

In 2009, after only three years on the market, the FDA connected Merck’s Januvia and Janumet to be the cause of acute pancreatitis, cancer and fatalities and required all labels to be sent out with a warning to the users.

0."/>